Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study

    loading  Checking for direct PDF access through Ovid



The objective of this study was to propose an optimal treatment regimen of meropenem in critically ill patients with severe nosocomial pneumonia.

Patients and methods

Among 55 patients in intensive care treated with 1 g of meropenem every 8 h for severe nosocomial pneumonia, 30 were assigned to intermittent infusion (II; over 0.5 h) and 25 to extended infusion (EI; over 3 h) groups. Based on plasma and epithelial lining fluid (ELF) concentrations determined at steady-state, pharmacokinetic modelling and Monte Carlo simulations were undertaken to assess the probability of attaining drug concentrations above the MIC for 40%–100% of the time between doses (%T > 1-fold and 4-fold MIC), for 1 or 2 g administered by either method.


Penetration ratio, measured by the ELF/plasma ratio of AUCs, was statistically higher in the EI group than in the II group (mean ± SEM: 0.29 ± 0.030 versus 0.20 ± 0.033, P = 0.047). Considering a maximum susceptibility breakpoint of 2 mg/L, all dosages and modes of infusions achieved 40%–100% T > 1-fold MIC in plasma, but none did so in ELF, and only the 2 g dose over EI achieved 40%–100% T > 4-fold MIC in plasma.


The optimum regimen to treat severe nosocomial pneumonia was 2 g of meropenem infused over 3 h every 8 h. This regimen achieved the highest pharmacodynamic targets both in plasma and in ELF.

Related Topics

    loading  Loading Related Articles